CHICAGO, March 17, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...
The projected fair value for Xeris Biopharma Holdings is US$6.17 based on 2 Stage Free Cash Flow to Equity Xeris Biopharma Holdings' US$5.03 share price indicates it is trading at similar levels ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range ...
CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a $742 million market cap pharmaceutical company whose stock has surged 116% over the past year, has announced the FDA approval of its ...
Xeris Biopharma (XERS) Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug Administration FDA approval for use as a diagnostic aid ...
Xeris Biopharma has strong revenue growth, with net product revenue reaching $203 million in 2024 and projected to hit $255–275 million in 2025. Key products include Gvoke for severe ...
CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a $742 million market cap pharmaceutical company whose stock has surged 116% over the past year, has announced the FDA approval of its ...
CHICAGO--(BUSINESS WIRE)--#GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...
1 Day XERS 5.70% DJIA 1.65% Russell 2K 2.53% Health Care/Life Sciences -0.59% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback